Vetsource’s Post

View organization page for Vetsource, graphic

23,803 followers

Veterinary Industry Summary June 23-29, 2024 Last week, Elanco announced updates regarding expected FDA approval timelines for two new products, Zenrelia and Credelio Quattro. According to Elanco, Zenrelia, a JAK inhibitor intended to control pruritus and atopic dermatitis in dogs, is expected to receive FDA approval late in the third quarter of this year, and Elanco foresees a fourth-quarter U.S. launch. Credelio Quattro, a broad-spectrum oral parasiticide, is expected to be approved during the fourth quarter of 2024, and a U.S. launch in early 2025.

To view or add a comment, sign in

Explore topics